Movatterモバイル変換


[0]ホーム

URL:


Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
Thehttps:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

NIH NLM Logo
Log inShow account info
Access keysNCBI HomepageMyNCBI HomepageMain ContentMain Navigation
pubmed logo
Advanced Clipboard
User Guide

Full text links

Silverchair Information Systems full text link Silverchair Information Systems
Full text links

Actions

Share

Randomized Controlled Trial
.2014 Aug;101(9):1077-83.
doi: 10.1002/bjs.9580. Epub 2014 Jun 30.

Randomized clinical trial of endovenous laser ablation versus steam ablation (LAST trial) for great saphenous varicose veins

Affiliations
Randomized Controlled Trial

Randomized clinical trial of endovenous laser ablation versus steam ablation (LAST trial) for great saphenous varicose veins

R R van den Bos et al. Br J Surg.2014 Aug.

Erratum in

  • Br J Surg. 2014 Oct;101(11):1484

Abstract

Background: The aim was to compare endovenous laser ablation (EVLA) and endovenous steam ablation (EVSA) for great saphenous varicose veins in a non-inferiority study.

Methods: Patients with primary great saphenous vein reflux were randomized to EVLA (940 nm) or EVSA (SVS™). Primary outcomes were treatment success (vein obliteration or abolition of reflux) [corrected] at 52 weeks, and Venous Clinical Severity Score (VCSS) at 12 weeks. Secondary outcomes were pain, satisfaction with treatment, duration of analgesia use and days lost from daily activities, changes in Aberdeen Varicose Vein Questionnaire (AVVQ) and EQ-5D™ scores after 12 weeks, and complications at 2 and 12 weeks.

Results: A total of 227 legs were treated (EVSA, 117; EVLA, 110); 36 legs treated with EVSA received a low dose and the remaining 81 a higher dose. At 1 year, the treatment success rate after high-dose EVSA was not inferior to that of EVLA: 92 (95 per cent confidence interval (c.i.) 86 to 98) versus 96 (92 to 100) per cent respectively. Changes in VCSS after 12 weeks were similar: -2·69 (95 per cent c.i. -2·34 to -3·04) and -2·51 (-2·10 to -2·93). AVVQ, EQ-5D™ and EQ VAS scores improved equally 12 weeks after both treatments. Patients treated with EVSA reported less postprocedural pain, fewer days of analgesia use, were more satisfied with therapy, and had a shorter convalescence. Complication rates were comparable.

Conclusion: The 1-year treatment success of high-dose EVSA was not inferior to that of EVLA. Several secondary outcomes were in favour of EVSA. Registration numberNCT02046967 (http://www.clinicaltrials.gov).

© 2014 BJS Society Ltd. Published by John Wiley & Sons Ltd.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

  • [Varicosis-Current treatment concepts].
    Lisii C, Heckenkamp J.Lisii C, et al.Chirurgie (Heidelb). 2024 May;95(5):415-426. doi: 10.1007/s00104-024-02063-4. Epub 2024 Apr 10.Chirurgie (Heidelb). 2024.PMID:38597983German.
  • Interventions for great saphenous vein incompetence.
    Whing J, Nandhra S, Nesbitt C, Stansby G.Whing J, et al.Cochrane Database Syst Rev. 2021 Aug 11;8(8):CD005624. doi: 10.1002/14651858.CD005624.pub4.Cochrane Database Syst Rev. 2021.PMID:34378180Free PMC article.Review.
  • A state-of-the-art review of quality-of-life assessment in venous disease.
    Cleman J, Xia K, Haider M, Nikooie R, Scierka L, Romain G, Attaran RR, Grimshaw A, Mena-Hurtado C, Smolderen KG.Cleman J, et al.J Vasc Surg Venous Lymphat Disord. 2024 Jul;12(4):101725. doi: 10.1016/j.jvsv.2023.101725. Epub 2023 Dec 19.J Vasc Surg Venous Lymphat Disord. 2024.PMID:38128828Free PMC article.Review.
  • S2k guidelines: diagnosis and treatment of varicose veins.
    Pannier F, Noppeney T, Alm J, Breu FX, Bruning G, Flessenkämper I, Gerlach H, Hartmann K, Kahle B, Kluess H, Mendoza E, Mühlberger D, Mumme A, Nüllen H, Rass K, Reich-Schupke S, Stenger D, Stücker M, Schmedt CG, Schwarz T, Tesmann J, Teßarek J, Werth S, Valesky E.Pannier F, et al.Hautarzt. 2022 May;73(Suppl 1):1-44. doi: 10.1007/s00105-022-04977-8. Epub 2022 Apr 19.Hautarzt. 2022.PMID:35438355Free PMC article.Review.No abstract available.
  • [Minimally invasive catheters in varicose vein treatment : New gold standard?].
    Böhler K.Böhler K.Dermatologie (Heidelb). 2023 Mar;74(3):163-170. doi: 10.1007/s00105-023-05113-w. Epub 2023 Feb 22.Dermatologie (Heidelb). 2023.PMID:36811641Free PMC article.Review.German.

Publication types

MeSH terms

Substances

Associated data

Related information

LinkOut - more resources

Full text links
Silverchair Information Systems full text link Silverchair Information Systems
Cite
Send To

NCBI Literature Resources

MeSHPMCBookshelfDisclaimer

The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.


[8]ページ先頭

©2009-2025 Movatter.jp